Trial Profile

A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Everolimus (Primary) ; Lapatinib (Primary) ; Nilotinib (Primary) ; Olaparib (Primary) ; Pazopanib (Primary) ; Sorafenib (Primary) ; Tremelimumab (Primary)
Indications Solid tumours
Focus Therapeutic Use
Acronyms MOST plus

29 Jul 2026 Planned End Date changed from 1 Oct 2027 to 1 Oct 2028.
29 Jul 2026 Planned End Date changed from 1 Oct 2027 to 1 Oct 2028.
29 Jul 2026 Planned primary completion date changed from 1 Jan 2026 to 1 Jan 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com